Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) has shared an announcement.
Immunovia has announced that its PancreaSure test has received a CPT Proprietary Laboratory Analyses code from the American Medical Association, effective October 1, 2025. This development marks an important step in Immunovia’s US market access strategy, facilitating the billing and reimbursement process for the PancreaSure test, although further steps are required to achieve full Medicare reimbursement.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to offer these tests to high-risk individuals.
Average Trading Volume: 3,244,107
Current Market Cap: SEK121.7M
Learn more about IMMNOV stock on TipRanks’ Stock Analysis page.